Study researchers found that function in daily life improved as migraine headache days reduced, and that migraine patients treated with galcanezumab had improved quality of life.
A systematic review was published focusing on migraine treatment and prevention using neurostimulation methods.
Taken every other day, rimegepant demonstrates efficacy for the preventive treatment of migraine.
High school students with migraine report a lower headache frequency if their school starts at 8:30 am or later compared with those who start school earlier in the day.
INP104 uses proprietary technology to deliver a lower dose (1.45mg) of dihydroergotamine mesylate (DHE) to the upper nasal space.
Novartis announced positive results from a phase 4 study comparing treatment with erenumab for episodic and chronic migraine.
This post hoc analysis assessed the effect of onabotulinumtoxinA on clinically meaningful changes in headache severity, headache-related impact, and QOL in adults with chronic migraine.
This phase 3, randomized, double-blind, placebo-controlled study assessed the efficacy and safety of IV infusion of eptinezumab to prevent migraine in adults with chronic migraine.
The FDA has expanded the approval of Nerivio® to include acute treatment of migraine with or without aura in patients aged 18 years and older with chronic migraine.
Qtrypta delivers zolmitriptan using the Company’s proprietary Adhesive Dermally-Applied Microarray (ADAM) technology that consists of a drug-coated microneedle patch.
